Hysbysiad gwybodaeth ymlaen llaw
Cais am gystadleuaeth yw’r hysbysiad hwn
Adran I:
Endid
contractio
I.1) Enw a chyfeiriad
Porton Biopharma
Salisbury
UK
E-bost: jeff.pike@portonbiopharma.com
NUTS: UKK
Cyfeiriad(au) rhyngrwyd
Prif gyfeiriad: https://portonbiopharma.bravosolution.co.uk
I.3) Cyfathrebu
Mae'r dogfennau caffael ar gael ar gyfer mynediad uniongyrchol anghyfyngedig a llawn, yn rhad ac am ddim ar:
https://portonbiopharma.bravosolution.co.uk
Gellir cael gwybodaeth ychwanegol o'r cyfeiriad uchod
Rhaid anfon tendrau neu geisiadau i gymryd rhan yn electronig at:
https://portonbiopharma.bravosolution.co.uk
Rhaid anfon tendrau neu geisiadau i gymryd rhan i'r cyfeiriad uchod:
Mae cyfathrebu electronig yn gofyn am ddefnyddio offer a dyfeisiau nad ydynt ar gael yn gyffredinol. Mae mynediad uniongyrchol anghyfgyfyngiedig a llawn i'r offer a dyfeisiau hyn yn bosibl, yn rhad ac am ddim, yn:
https://portonbiopharma.bravosolution.co.uk
I.4) Y math o awdurdod contractio
Corff a lywodraethir gan gyfraith gyhoeddus
I.5) Prif weithgaredd
Iechyd
Adran II: Gwrthrych
II.1) Cwmpas y caffaeliad
II.1.1) Teitl
PBL — GMP Drug Substance and Drug Product
II.1.2) Prif god CPV
33600000
II.1.3) Y math o gontract
Cyflenwadau
II.1.4) Disgrifiad byr
PBL has a requirement for a contract manufacturing organisation (CMO) to manufacture a recombinant protein, expressed in bacteria. The project will include technical transfer and manufacture of clinical-grade GMP drug substance and drug product. Parties interested in either or both stages (drug substance and/or drug product) should reply and agree to exchange a CDA prior to the tender.
II.1.6) Gwybodaeth am lotiau
Mae’r contract hwn wedi’i rannu’n lotiau:
Ydy
Gellir cyflwyno tendrau ar gyfer pob lot
II.2) Disgrifiad
Rhif y Lot 1 - Drug Substance
II.2.1) Teitl
Drug Substance
II.2.2) Cod(au) CPV ychwanegol
33600000
II.2.3) Man cyflawni
Cod NUTS:
UKK
II.2.4) Disgrifiad o’r caffaeliad
PBL has a requirement for a contract manufacturing organisation (CMO) to manufacture a recombinant protein, expressed in bacteria. The project will include technical transfer and manufacture of clinical-grade GMP drug substance and drug product. Parties interested in either or both stages (drug substance and/or drug product) should reply and agree to exchange a CDA prior to the tender.
II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd
Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd:
Na
Rhif y Lot 2
II.2.1) Teitl
Drug Product
II.2.2) Cod(au) CPV ychwanegol
33600000
II.2.3) Man cyflawni
Cod NUTS:
UKK
II.2.4) Disgrifiad o’r caffaeliad
PBL has a requirement for a contract manufacturing organisation (CMO) to manufacture a recombinant protein, expressed in bacteria. The project will include technical transfer and manufacture of clinical-grade GMP drug substance and drug product. Parties interested in either or both stages (drug substance and/or drug product) should reply and agree to exchange a CDA prior to the tender.
II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd
Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd:
Na
Rhif y Lot 3
II.2.1) Teitl
Drug Substance and Drug Product
II.2.2) Cod(au) CPV ychwanegol
33600000
73200000
II.2.3) Man cyflawni
Cod NUTS:
UKK
II.2.4) Disgrifiad o’r caffaeliad
PBL has a requirement for a contract manufacturing organisation (CMO) to manufacture a recombinant protein, expressed in bacteria. The project will include technical transfer and manufacture of clinical-grade GMP drug substance and drug product. Parties interested in either or both stages (drug substance and/or drug product) should reply and agree to exchange a CDA prior to the tender.
II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd
Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd:
Na
Section IV: Gweithdrefn
IV.1) Disgrifiad
IV.1.1) Y math o weithdrefn
Gweithdrefn gyfyngedig
IV.1.8) Gwybodaeth am Gytundeb Caffael y Llywodraeth (GPA)
The procurement is covered by the Government Procurement Agreement:
Ydy
IV.2) Gwybodaeth weinyddol
IV.2.2) Terfyn amser i ddatganiadau o ddiddordeb ddod i law
Dyddiad:
21/08/2020
Amser lleol: 17:00
IV.2.4) Ym mha iaith/ieithoedd y gellir cyflwyno tendrau neu geisiadau i gymryd rhan
EN
Section VI: Gwybodaeth ategol
VI.2) Gwybodaeth am lifau gwaith electronig
Defnyddir archebion electronig
Derbynnir anfonebau electronig
VI.4) Gweithdrefnau adolygu
VI.4.1) Corff adolygu
Porton Biopharma Ltd
Salisbury
UK
VI.5) Dyddiad anfon yr hysbysiad hwn
16/07/2020